Abstract The 4-anilinoquinazolines (gefitinib, erlotinib and lapatinib) are members of a class
of potent and selective inhibitors of the human epidermal growth factor receptor (HER) family …

Drug interactions are an on-going concern in the treatment of cancer, especially when
targeted therapies, such as tyrosine kinase inhibitors (TKI) or mammalian target of …

Purpose To determine whether the addition of pemetrexed to gefitinib (P+ G) provides
clinical benefit, compared with gefitinib monotherapy, in patients with advanced …

Highlights•Complete overview on exposure–response relationships for TKIs used in solid
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …

Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-
small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine …

Background This randomised controlled phase 2 study compared pemetrexed and erlotinib
in combination with either agent alone in terms of efficacy and safety as second-line …

BACKGROUND: Platinum-based chemotherapy is the standard of care for ovarian cancer
and non-small cell lung cancer (NSCLC). However, resistance to platinum agents invariably …

Introduction: Due to their multiple effects, glucocorticoids (GCs) have versatile medical uses.
They can regulate many xenobiotic-metabolizing enzymes of the cytochrome P450 (CYP) …

Zhou X, Tao H, Shi KH. Drug Des Devel Ther. 2018; 12: 1–8. The Editor and Publisher of
Drug Design, Development and Therapy wish to retract the published article. Concerns were …

Introduction: Patients with epidermal growth factor receptor (EGFR) mutation positive non–
small-cell lung cancer exhibited marked response to gefitinib or erlotinib. In most cases …